Physician profile
Tyler Wolf
NPI 1205524220
$2,293.77
in general payments reported to CMS, 2019-2025
18 companies · $823 in 2025
The $823 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $124 · 2024: $1,346 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675 · Travel and Lodging: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.60 |
| Travel and Lodging | $619.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,578.25 | 2023-2025 | Watchman, Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.13 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.77 | 2025 | Jardiance |
| Medtronic, INC. | $56.11 | 2024-2025 | Azure Xt Dr Mri Surescan, Symplicity G3 |
| Scpharmaceuticals INC. | $40.83 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $40.33 | 2024-2025 | Camzyos |
| Astrazeneca Pharmaceuticals Lp | $39.05 | 2024-2025 | Farxiga |
| Abiomed | $31.53 | 2025 | |
| Daiichi Sankyo INC. | $28.82 | 2025 | Injectafer |
| Pfizer INC. | $25.54 | 2025 | |
| Biosense Webster, INC. | $24.38 | 2024 | Carto 3 |
| Biotronik INC. | $23.69 | 2024 | Biomonitor, Pamira, Acticor 7 Vr-T Dx |
| Merck Sharp & Dohme LLC | $20.84 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $18.29 | 2025 | |
| Chiesi USA, INC. | $18.04 | 2024 | Kengreal, Cleviprex |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $17.00 | 2023 | Onpattro |
| Bridgebio Pharma, INC. | $16.96 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $15.21 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.